Shots:
- The CHMP has granted positive opinion to Yuvanci [macitentan (10mg) + tadalafil (40mg)] as a substitution therapy of PAH adults, based on P-III (A DUE) study
- The P-III (A DUE) trial assessed Yuvanci STCT vs macitentan (10mg) & tadalafil (40mg) alone in PAH patients (n=187). Subjects with PVR ≥240 dyn×s/cm5 randomly received M/T STCT (n=108), macitentan alone (n=35) or tadalafil alone (n=44), QD
- Trial reached its 1EP, showing reduced PVR (as a ratio of wk.16 to baseline) of 29% (effect of 0.71) vs macitentan & 28% (effect of 0.72) vs tadalafil, with similar efficacy observed in subgroups of age, sex, race & baseline WHO FC as well as among treatment-naïve or experienced patients (with ERA or PDE5i)
Ref: Johnson & Johnson | Image: Johnson & Johnson | Press Release
Related News:- LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
